Related Experiment Video
Updated: Oct 21, 2025
08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
9.3K
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy.
Andrew Wolf1, Enrique Alvarez1
1Department of Neurology, University of Colorado School of Medicine, Aurora.
Neurology. Clinical Practice
|September 6, 2021
Summary
Managing multiple sclerosis (MS) patients on immunosuppressive disease-modifying therapies (DMTs) during COVID-19 is challenging. This review examines COVID-19 outcomes and vaccine effectiveness in MS patients on specific DMTs, offering management recommendations.
Area of Science:
- Neurology
- Immunology
- Infectious Diseases
Background:
- The COVID-19 pandemic presents unique challenges for neurologists managing patients with multiple sclerosis (MS).
- Disease-modifying therapies (DMTs) for MS often have immunosuppressive effects, increasing infection risk and potentially impacting vaccine response.
- MS patients are already vulnerable due to neurologic deficits.
Purpose of the Study:
- To review early data on COVID-19 outcomes in MS patients.
- To discuss vaccine effectiveness in MS patients on anti-CD20 and sphingosine-1-phosphate receptor agents.
- To provide recommendations for COVID-19 vaccination strategies in MS patients.
Main Methods:
- Literature review of early COVID-19 data in MS patients.
- Analysis of existing data on vaccine effectiveness in MS patients on specific DMTs.
- Synthesis of information to formulate clinical recommendations.
Main Results:
- Early data on COVID-19 outcomes in MS patients are presented.
- Vaccine effectiveness in MS patients on anti-CD20 and S1P receptor agents is discussed, considering their mechanisms of action.
- Potential attenuating effects of certain DMTs on vaccine response are highlighted.
Conclusions:
- Optimizing COVID-19 vaccine strategies for MS patients on DMTs is crucial.
- Further research is needed to fully understand vaccine efficacy and long-term outcomes.
- Personalized management approaches are recommended for this vulnerable population.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
01:24Parkinson's Disease: Treatment
451
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
451
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
289
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
289
01:21Rheumatic Heart Disease III: Medical Management
65
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
65
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
261
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
261
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
241
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
241